Montelukaat in pregnancy
Reading File
Finding Sources
Searching PubMed
montelukast pregnancy safety
Reading File
Reading File
Reading Article
Here is a comprehensive summary of montelukast use in pregnancy:
Montelukast (Singulair) in Pregnancy
Drug Class & Mechanism
Montelukast is a leukotriene receptor antagonist (LTRA). Leukotrienes are arachidonic acid metabolites that cause bronchoconstriction, mucus secretion, and increased vascular permeability — montelukast blocks these effects at the cysteinyl leukotriene receptor.
FDA Pregnancy Category
Historically Category B — animal studies show no fetal harm, but human data remain limited.
Indications During Pregnancy
- Alternative treatment for mild persistent asthma
- Adjunctive therapy for moderate-to-severe persistent asthma (added to inhaled corticosteroids)
- Can be used before exercise in patients with exercise-induced bronchoconstriction
- Less effective as a single agent than inhaled corticosteroids (ICS) and less effective than LABAs as add-on therapy — ICS remain the preferred first-line anti-inflammatory agent
The risks of poorly controlled asthma far outweigh the possible hazards of drug therapy. — Creasy & Resnik's Maternal-Fetal Medicine, p. 1412
Safety Data
Animal Studies
Reassuring — no significant teratogenicity observed for montelukast or zafirlukast. — Murray & Nadel's Textbook of Respiratory Medicine
Human Studies
| Outcome | Finding |
|---|---|
| Congenital anomalies (CA) | No significant increase — RR 1.13 (95% CI 0.74–1.73, p=0.56) |
| Preterm delivery | Possible association — OR 1.82 (95% CI 1.35–2.45, p<0.001) |
| Low birthweight | Possible association (same pooled estimate as preterm) |
| Spontaneous abortion | Inconclusive — OR 1.03 (95% CI 0.72–1.5), high heterogeneity (I²=73%) |
| Neurodevelopmental outcomes | No significant risk identified |
| Major malformations | Large cohort studies have not shown an increased risk |
— Based on 2024 systematic review & meta-analysis (Fareed et al., Congenital Anomalies, PMID 39129058)
Key textbook statement (Murray & Nadel):
"Several large cohort studies of pregnant women exposed to montelukast have not shown an increased risk of congenital malformations."
Lactation
Montelukast and zafirlukast are considered most likely compatible with breastfeeding. — Dermatology 2-Volume Set 5e
Comparators — Other LTRAs in Pregnancy
| Drug | Recommendation |
|---|---|
| Montelukast | Reassuring animal data; can be continued/used in pregnancy |
| Zafirlukast | Also reassuring animal data; generally acceptable |
| Zileuton | Not recommended — limited human data and nonreassuring animal data |
Clinical Guidance
- Continue montelukast if a patient was already responding well to it before pregnancy — abrupt discontinuation risks asthma exacerbation, which carries greater fetal risk than the drug.
- Prefer ICS (budesonide) as the first-line anti-inflammatory — budesonide is the best-studied agent in pregnancy.
- LTRAs are an option when ICS are not tolerated or not sufficient alone.
- Maintain objective lung function monitoring (spirometry at baseline, home peak flow monitoring).
Recent Evidence (2024 Meta-Analysis)
Fareed et al. (2024) — Systematic Review & Meta-Analysis, PMID 39129058 — found a relatively favorable safety profile for montelukast in pregnancy, particularly regarding major congenital anomalies, but flagged potential signals for preterm delivery and low birthweight that warrant further research. Confounding by indication (i.e., women with worse asthma may be more likely to receive montelukast and also have worse outcomes) limits interpretation.
Bottom line: Montelukast can be used in pregnancy when clinically needed, particularly if the patient was already on it or if ICS alone are insufficient. The teratogenic risk appears low, but caution is warranted regarding preterm birth signals. The primary principle remains: uncontrolled asthma poses more risk to mother and fetus than the drug itself.
This is a shared conversation. Sign in to Orris to start your own chat.